VKTX Stock Recent News

The sell-off in unprofitable stocks has hit tech and growth sectors hard, with investors seeking safety in healthcare and consumer staples. Viking Therapeutics remains speculative despite progress in its clinical portfolio, notably the VK2735 program for obesity. VKTX's $900M cash reserves and sufficient liquidity mitigate near-term funding risks, crucial amid current market uncertainties and lack of partnerships.

Viking Therapeutics stock toppled Tuesday after the biotech company inked a $150 million manufacturing deal for its weight-loss drug, VK2735. The post Viking Therapeutics Just Inked A $150 Million Manufacturing Deal.

Long-Term Agreement Secures Dedicated Capacity for Multi-Ton Annual Supply of VK2735 Active Pharmaceutical Ingredient Secures Dedicated Fill/Finish Capacity for 100 Million Annual Autoinjector Supply and Additional 100 Million Annual Vial/Syringe Supply Provides Annual Capacity of Over 1 Billion Oral Tablets Viking to Make Prepayments Totaling $150 Million Between 2025-2028 SAN DIEGO , March 11, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it has signed a broad, multi-year manufacturing agreement with CordenPharma, an industry-leading contract development and manufacturing organization (CDMO), covering both the active pharmaceutical ingredient (API) and final finished product supply for its VK2735 program for obesity. The agreement provides Viking with sufficient long-term supply of both subcutaneous and oral

Viking Therapeutics' stock declined by 37% following a downgrade to "hold" in December, anticipating competitive pressures from Novo Nordisk's CagriSema Phase 3 results. The company's GIP/GLP-1 agonist, VK2735, appears undifferentiated, facing intense competition from existing and emerging obesity treatments. Plans to launch VK2735 with an auto-injector could delay regulatory approval, offering minimal patient benefit over existing prefilled pens.

In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $29.10, indicating a +1.46% shift from the previous trading day.

In February, twenty-three new analysts joined Seeking Alpha, offering diverse stock picks and insights, from biotech to automotive and energy sectors. Analysts provided ratings from Strong Sell to Strong Buy, with detailed justifications based on market trends, company fundamentals, and sector-specific challenges. Key investment theses include bearish views on German automotive and LNG sectors, while bullish on biotech, fintech, and energy companies.

SAN DIEGO , March 4, 2025 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the company will participate at multiple upcoming investor conferences.  Details of the company's participation are as follows: Leerink Partners Global Healthcare Conference 2025 Details: Viking management will participate in a fireside chat and in 1-on-1 meetingsConference Date: March 10-12, 2025 Fireside Chat Timing: 9:20 – 9:50 a.m.

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $28.87, denoting a +0.7% change from the preceding trading day.

Viking Therapeutics (VKTX 3.06%) and Novavax (NVAX -3.55%) were two of the big winners in the biotech industry last year. Both companies saw their shares rise significantly; the former had exciting clinical progress, while the latter signed a lucrative deal with a biotech giant that had Wall Street cheering.

Investors looking for growth in recent times have piled into stocks in artificial intelligence and quantum computing. But these aren't the only areas that offer the potential for explosive revenue growth and stock performance.